Navigation Links
Infusing chemotherapy into the liver gives extra months of disease-free life in melanoma patients
Date:9/23/2011

Stockholm, Sweden: Melanoma of the eye (ocular or uveal melanoma) frequently spreads to the liver and, once this has happened, there is no effective treatment and patients die within an average of two to four months. Only about one in ten patients live for a year. Now, final results from a phase III study have demonstrated that a new treatment significantly extends the time patients can live without the disease progressing.

James Pingpank, associate professor of surgery at the University of Pittsburgh Cancer Institute (Pittsburgh, USA), will tell the 2011 European Multidisciplinary Cancer Congress [1] on Saturday that, by April 2011, the length of time that patients survived without the metastases spreading further in the liver (disease progression) was an average of 8.1 months for those receiving the new treatment compared to 1.6 months in the group of patients that had been randomised to receive the best alternative care.

The new treatment is called percutaneous hepatic perfusion (PHP) and is designed to saturate the liver with high doses of chemotherapy without affecting the rest of the body. The chemotherapy drug melphalan is infused directly into the liver via an intra-arterial catheter over a period of 30 minutes. Blood in the veins leading out of the liver is then captured and filtered through a specially designed, double-balloon catheter to extract the drug before the cleaned blood is returned to the body. This enables the drug to be delivered directly to the liver to target the melanoma metastases there, but in a minimally invasive manner. The patient is monitored in intensive care before being allowed home. Once the liver has recovered from the toxicity of the treatment, the procedure is repeated every four to eight weeks.

In a phase III, randomised trial that took place in nine US clinics, 93 patients were randomised to receive PHP or best alternative care between February 2006 and July 2009. Best alternative care (BAC) wa
'/>"/>

Contact: Emma Mason
wordmason@mac.com
ECCO-the European CanCer Organisation
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. New developments in nanotechnology tackle the 2 biggest problems associated with chemotherapy
2. Roche/Genentech/Chugais Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer
3. Scientists identify microRNA as possible cause of chemotherapy resistance
4. Study evaluates costs and benefits of new chemotherapy drugs
5. Researchers find new chemotherapy combination shows promise in endometrial cancer
6. Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
7. Recommended Dental Care for Chemotherapy Patients -- Advice from Steven McConnell, DDS
8. Pregnant women can receive breast cancer chemotherapy without endangering health of their babies
9. Making Your Way Through the Fog of Chemotherapy
10. Interruption of Menstrual Cycle by Chemotherapy Associated with Improved Survival in Early Breast Cancer
11. Ancient Chinese herbal recipe eases side effects of chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2015)... York (PRWEB) April 25, 2015 ... for vaginal mesh lawsuits filed against C.R. Bard, ... District Court, Southern District of West Virginia. According ... Scheduling Conference was convened that day, after certain ... Long Form Complaint. The Order directed that any ...
(Date:4/25/2015)... Henderson, NV (PRWEB) April 25, 2015 ... Program is still eliciting the excitement of the public ... well into the months of May and June. ... Wellness™ held their biannual tradition of "Special Prayers." More ... who had attended previous Special Prayers and have reported ...
(Date:4/25/2015)... (PRWEB) April 25, 2015 Parker and Sons ... and cooling, has spiked in Arizona alongside the growing economy. ... additional forty employees for April to help account for the ... forty employees in April is something we are enthusiastic about. ... said Paul Kelly, president at Parker and Sons. , Indeed, ...
(Date:4/25/2015)... Dallas, TX/Minneapolis, MN (PRWEB) April 25, 2015 ... as the recipient of RFID Journal’s annual Best Implementation ... company that has demonstrated the best use of RFID ... operations. The winner is the company that best demonstrates ... The award was presented at RFID Journal Live! 2015 ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 Constellations Recovery ... residence in Westchester County. Just 35 miles from New ... individuals back into everyday life while recovering from addiction. ... 7, 2015, will allow therapists, doctors and treatment centers ... learn more about the opportunities offered by Constellations Recovery., ...
Breaking Medicine News(10 mins):Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 4Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 2Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 3Health News:Parker and Sons Plans to Expand in 2015 2Health News:Seeonic’s Industry Leading Technology Powers Interstate Batteries to Winning Award 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 3
... C did little to protect healthy men, either , , ... released Sunday cast doubt on the cardiac benefits of ... researchers found that low-dose aspirin did not reduce the ... diabetes. , Second, Harvard researchers concluded that neither vitamin ...
... Nov. 9, 2007 Mark Twain, a skeptic of the ... Man?" that humans do not command their minds or the ... a speaker identified as "old man" says in the essay. ... reflection or the need of it." , Twain,s views get ...
... interference when placed too closely to pacemakers, ICDs , , ... for your iPod into your coat pocket might not ... normal functioning of your implanted cardiac device. ... Association,s annual scientific sessions, in New Orleans, report that ...
... 9 The NHS Human,Services Foundation held its fifth ... the Hyatt Regency Penn,s Landing in Philadelphia. This event ... supports the mission,of NHS Human Services, one of the ... Every year the Foundation presents the Leading the ...
... Academy of Ophthalmology (Academy) and European Society of Ophthalmology ... meeting in the world, is in session November ... Center, Atlanta. Offerings include 277 continuing medical education ... transfer courses, and more than 100 hours of scientific ...
... Cataract Surgery Patients can Better Understand Their Condition at CataractSurgery.com ... ... Cataract surgery patients and their caregivers now have a new online ... . Cataracts affect nearly 20 million Americans age 60 ...
Cached Medicine News:Health News:Aspirin Doesn't Guard Diabetics Against Heart Disease 2Health News:Aspirin Doesn't Guard Diabetics Against Heart Disease 3Health News:Aspirin Doesn't Guard Diabetics Against Heart Disease 4Health News:Simple brain mechanisms explain arbitrary human visual decisions 2Health News:Simple brain mechanisms explain arbitrary human visual decisions 3Health News:MP3 Player Headphones May Throw Off Cardiac Devices 2Health News:MP3 Player Headphones May Throw Off Cardiac Devices 3Health News:Gala Raises Funds for NHS Human Services 2Health News:AAO-SOE Joint Meeting research highlights 2Health News:AAO-SOE Joint Meeting research highlights 3Health News:AAO-SOE Joint Meeting research highlights 4Health News:Alcon Sponsors Online Educational Initiative for Patients Considering Cataract Surgery 2
(Date:4/24/2015)... 2015 Research and Markets ... of the "Lab Accessories Market by ... Station) & End User (OEM/Biotechnology & Pharmaceutical ... 2020" report to their offering. ... expected to reach $504.7 million by 2020 ...
(Date:4/24/2015)... , April 24, 2015  Lannett Company, Inc. ... amended and increased its five-year revolving credit facility to ... an accordion feature that will allow the company to ... additional $30.0 million, subject to securing additional commitments from ... of the credit facility remains December 18, 2018.   ...
(Date:4/23/2015)... NORTH CHICAGO, Ill. , April 24, 2015 /PRNewswire/ ... U.S. Food and Drug Administration (FDA) has accepted its ... the company,s, all-oral, interferon-free, two direct-acting antiviral treatment of ... is for the treatment of adults with chronic genotype ... AbbVie,s regimen is the first all-oral, interferon-free therapy being ...
Breaking Medicine Technology:Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 2Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 3Lannett Expands Revolving Credit Facility To $120 Million 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7
... patch, Duragen is a matrix for ... handles and conforms similar to normal ... matrix for dural closure. Remarkable onlay ... defects. Fully resorbed following complete tissue ...
The Bovie IDS Series are the latest electrosurgical generators with fully digital implementation....
Elmed electrosurgical systems for major surgery....
Aaron 1250 is a multipurpose electrosurgical generator with monopolar and bi-polar functions....
Medicine Products: